Data as of Q4 2025 (Dec 31, 2025)

EUPRAXIA PHARMACEUTICALS INC.

(EPRX)

Financial Statements · SEC EDGAR XBRL

Revenue
$0
Net Income
-$38.6M
-51.3%
EPS
$-1.03
-35.5%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Revenues
Total Revenues
Operating Expenses & Income
Research & Development
Total Operating Expenses
Non-Operating Income/Expense
Interest Income/Expense
Other Non-Operating Income
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)
FY 2025
FY 2024
FY 2023
FY 2022
$0
$0
$0
-
$0
$0
$0
-
$21.3M
$16.1M
$20.4M
$13.6M
$38.4M
$27.0M
$27.8M
$17.6M
$0
$604K
$1.2M
$983K
-$153K
$1.3M
-$1.1M
-$1.4M
-$38.6M
-$25.7M
-$28.9M
-$19.0M
$19K
$2K
$36K
$0
-$38.6M
-$25.5M
-$28.2M
-$18.5M
$-1.03
$-0.76
$-1.17
$-0.96
$-1.03
$-0.76
$-1.17
$-0.96
40.0M
33.9M
24.1M
19.3M